NasdaqGS:CNST

Stock Analysis Report

Executive Summary

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Constellation Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

32.9%

CNST

1.7%

US Biotechs

0.5%

US Market


1 Year Return

85.6%

CNST

-7.2%

US Biotechs

6.8%

US Market

Return vs Industry: CNST exceeded the US Biotechs industry which returned -7.2% over the past year.

Return vs Market: CNST exceeded the US Market which returned 6.8% over the past year.


Shareholder returns

CNSTIndustryMarket
7 Day32.9%1.7%0.5%
30 Day74.9%-3.4%-0.8%
90 Day34.4%-1.3%-0.9%
1 Year85.6%85.6%-6.3%-7.2%9.2%6.8%
3 Yearn/a14.8%10.9%45.6%36.2%
5 Yearn/a-2.3%-7.0%63.2%45.4%

Price Volatility Vs. Market

How volatile is Constellation Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Constellation Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

4.89x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CNST's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CNST's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CNST is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CNST is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CNST's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CNST is overvalued based on its PB Ratio (4.9x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Constellation Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

-17.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CNST is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CNST is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CNST is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if CNST's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CNST's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CNST is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Constellation Pharmaceuticals performed over the past 5 years?

-36.8%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CNST is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare CNST's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CNST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: CNST has a negative Return on Equity (-113.23%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: CNST is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CNST is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Constellation Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CNST's short term assets ($100.7M) exceeds its short term liabilities ($17.2M)

Long Term Liabilities: CNST's short term assets (100.7M) exceeds its long term liabilities (29.9M)


Debt to Equity History and Analysis

Debt Level: CNST's debt to equity ratio (29.1%) is considered satisfactory

Reducing Debt: Insufficient data to determine if CNST's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: CNST has a low level of unsold assets or inventory.

Debt Coverage by Assets: CNST's debt is covered by short term assets (assets are 5.144410x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CNST has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CNST has less than a year of cash runway if free cash flow continues to reduce at historical rates of -25.2% each year


Next Steps

Dividend

What is Constellation Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CNST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CNST's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CNST's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CNST's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CNST's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Constellation Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.5yrs

Average management tenure


CEO

Jigar Raythatha 0

2.6yrs

Tenure

US$4,703,254

Compensation

Mr. Jigar Raythatha has been the President, Chief Executive Officer and Director of Constellation Pharmaceuticals, Inc. since March 2017. Mr. Raythatha served as the Chief Business Officer at Jounce Therap ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Jigar's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Jigar's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.5yrs

Average Tenure

55yo

Average Age

Experienced Management: CNST's management team is considered experienced (2.5 years average tenure).


Board Age and Tenure

2.4yrs

Average Tenure

63yo

Average Age

Experienced Board: CNST's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$11,319,99407 Oct 19
Ponoi Capital
EntityCompany
Shares1,331,764
Max PriceUS$8.50
BuyUS$680,00007 Oct 19
Topspin Partners LP
EntityCompany
Shares80,000
Max PriceUS$8.50
BuyUS$23,999,99704 Oct 19
VR Adviser, LLC
EntityCompany
Shares2,823,529
Max PriceUS$8.50

Ownership Breakdown


Management Team

  • Emma Reeve (58yo)

    Senior VP

    • Tenure: 2yrs
    • Compensation: US$1.44m
  • Brenda Sousa (55yo)

    Senior Vice President of Human Resources & Operations

    • Tenure: 2.5yrs
  • Jigar Raythatha

    President

    • Tenure: 2.6yrs
    • Compensation: US$4.70m
  • David Allis

    Co-Founder

    • Tenure: 11.8yrs
  • Karen Valentine (47yo)

    Chief Legal Officer & General Counsel

    • Tenure: 1.3yrs
  • Ron Aldridge (65yo)

    Senior Director of Investor Relations

    • Tenure: 0yrs
  • Danny Reinberg

    Co-Founder

    • Tenure: 11.8yrs
  • Yang Shi

    Co-Founder

    • Tenure: 11.8yrs
  • Adrian Senderowicz (55yo)

    Senior VP & Chief Medical Officer

    • Tenure: 2.3yrs
    • Compensation: US$1.13m
  • Patrick Trojer (46yo)

    Chief Scientific Officer

    • Tenure: 0.9yrs

Board Members

  • Tony Evnin (78yo)

    Director

    • Tenure: 11.5yrs
    • Compensation: US$24.37k
  • Bob Tepper (63yo)

    Director

    • Tenure: 11.5yrs
    • Compensation: US$21.64k
  • Mark Goldsmith (57yo)

    Chairman of the Board

    • Tenure: 0yrs
    • Compensation: US$204.51k
  • Jigar Raythatha

    President

    • Tenure: 2.6yrs
    • Compensation: US$4.70m
  • David Livingston (77yo)

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Scott Lowe

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Jim Audia (63yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: US$230.33k
  • Steve Hoerter (48yo)

    Director

    • Tenure: 1.1yrs
    • Compensation: US$177.29k
  • Pam Sharma

    Member of Scientific Advisory Board

    • Tenure: 2.4yrs
  • Robert Schreiber

    Member of Scientific Advisory Board

    • Tenure: 2.4yrs

Company Information

Constellation Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Constellation Pharmaceuticals, Inc.
  • Ticker: CNST
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$426.028m
  • Shares outstanding: 33.47m
  • Website: https://www.constellationpharma.com

Number of Employees


Location

  • Constellation Pharmaceuticals, Inc.
  • 215 First Street
  • Suite 200
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CNSTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2018

Biography

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 00:52
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.